These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 29616704)

  • 1. Minimizing the Sample Sizes of Clinical Trials on Preclinical and Early Symptomatic Stage of Alzheimer Disease.
    Luo J; Weng H; Morris JC; Xiong C
    J Prev Alzheimers Dis; 2018; 5(2):110-119. PubMed ID: 29616704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subsets of a large cognitive battery better power clinical trials on early stage Alzheimer's disease.
    Xiong C; Weng H; Bennett DA; Boyle PA; Shah RC; Fague S; Hall CB; Lipton RB; Morris JC
    Neuroepidemiology; 2014; 43(2):131-9. PubMed ID: 25376544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease.
    Langbaum JB; Hendrix SB; Ayutyanont N; Chen K; Fleisher AS; Shah RC; Barnes LL; Bennett DA; Tariot PN; Reiman EM
    Alzheimers Dement; 2014 Nov; 10(6):666-74. PubMed ID: 24751827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease.
    Tarawneh R; D'Angelo G; Crimmins D; Herries E; Griest T; Fagan AM; Zipfel GJ; Ladenson JH; Morris JC; Holtzman DM
    JAMA Neurol; 2016 May; 73(5):561-71. PubMed ID: 27018940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer's Disease Cooperative Study Cognitive Function Instrument.
    Amariglio RE; Donohue MC; Marshall GA; Rentz DM; Salmon DP; Ferris SH; Karantzoulis S; Aisen PS; Sperling RA;
    JAMA Neurol; 2015 Apr; 72(4):446-54. PubMed ID: 25706191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypothetical Preclinical Alzheimer Disease Groups and Longitudinal Cognitive Change.
    Soldan A; Pettigrew C; Cai Q; Wang MC; Moghekar AR; O'Brien RJ; Selnes OA; Albert MS;
    JAMA Neurol; 2016 Jun; 73(6):698-705. PubMed ID: 27064267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imaging.
    Zhao Y; Raichle ME; Wen J; Benzinger TL; Fagan AM; Hassenstab J; Vlassenko AG; Luo J; Cairns NJ; Christensen JJ; Morris JC; Yablonskiy DA
    Neuroimage; 2017 Mar; 148():296-304. PubMed ID: 27989773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease.
    Edmonds EC; Delano-Wood L; Galasko DR; Salmon DP; Bondi MW;
    J Alzheimers Dis; 2015; 47(1):231-42. PubMed ID: 26402771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Statistically-Derived Composite Measures for Assessing the Efficacy of Disease-Modifying Therapies in Prodromal Alzheimer's Disease Trials: An AIBL Study.
    Burnham SC; Raghavan N; Wilson W; Baker D; Ropacki MT; Novak G; Ames D; Ellis K; Martins RN; Maruff P; Masters CL; Romano G; Rowe CC; Savage G; Macaulay SL; Narayan VA; ;
    J Alzheimers Dis; 2015; 46(4):1079-89. PubMed ID: 26402634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of High-Frequency In-Home Monitoring Data May Reduce Sample Sizes Needed in Clinical Trials.
    Dodge HH; Zhu J; Mattek NC; Austin D; Kornfeld J; Kaye JA
    PLoS One; 2015; 10(9):e0138095. PubMed ID: 26379170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is comprehensiveness critical? Comparing short and long format cognitive assessments in preclinical Alzheimer disease.
    Hassenstab J; Nicosia J; LaRose M; Aschenbrenner AJ; Gordon BA; Benzinger TLS; Xiong C; Morris JC
    Alzheimers Res Ther; 2021 Sep; 13(1):153. PubMed ID: 34517889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriers.
    Ayutyanont N; Langbaum JB; Hendrix SB; Chen K; Fleisher AS; Friesenhahn M; Ward M; Aguirre C; Acosta-Baena N; Madrigal L; Muñoz C; Tirado V; Moreno S; Tariot PN; Lopera F; Reiman EM
    J Clin Psychiatry; 2014 Jun; 75(6):652-60. PubMed ID: 24816373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ADCS Prevention Instrument Project: overview and initial results.
    Ferris SH; Aisen PS; Cummings J; Galasko D; Salmon DP; Schneider L; Sano M; Whitehouse PJ; Edland S; Thal LJ;
    Alzheimer Dis Assoc Disord; 2006; 20(4 Suppl 3):S109-23. PubMed ID: 17135805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Profiles of Cognitive Change in Preclinical and Prodromal Alzheimer's Disease Using Change-Point Analysis.
    Williams OA; An Y; Armstrong NM; Kitner-Triolo M; Ferrucci L; Resnick SM
    J Alzheimers Dis; 2020; 75(4):1169-1180. PubMed ID: 32390623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detecting Non-cognitive Features of Prodromal Neurodegenerative Diseases.
    Seifan A; Ganzer CA; Ryon K; Lin M; Mahmudur R; Adolfo H; Shih C; Jacobs AR; Greenwald M; Isaacson RS
    Curr Aging Sci; 2019; 11(4):242-249. PubMed ID: 30845903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attitudes toward clinical trials across the Alzheimer's disease spectrum.
    Nuño MM; Gillen DL; Dosanjh KK; Brook J; Elashoff D; Ringman JM; Grill JD
    Alzheimers Res Ther; 2017 Oct; 9(1):81. PubMed ID: 28978335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prodromal Dementia with Lewy Bodies and Prodromal Alzheimer's Disease: A Comparison of the Cognitive and Clinical Profiles.
    Sadiq D; Whitfield T; Lee L; Stevens T; Costafreda S; Walker Z
    J Alzheimers Dis; 2017; 58(2):463-470. PubMed ID: 28453473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Trial-Ready Cohort for Preclinical and Prodromal Alzheimer's Disease (TRC-PAD): Experience from the First 3 Years.
    Walter S; Langford OG; Clanton TB; Jimenez-Maggiora GA; Raman R; Rafii MS; Shaffer EJ; Sperling RA; Cummings JL; Aisen PS
    J Prev Alzheimers Dis; 2020; 7(4):234-241. PubMed ID: 32920625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amyloid-β, anxiety, and cognitive decline in preclinical Alzheimer disease: a multicenter, prospective cohort study.
    Pietrzak RH; Lim YY; Neumeister A; Ames D; Ellis KA; Harrington K; Lautenschlager NT; Restrepo C; Martins RN; Masters CL; Villemagne VL; Rowe CC; Maruff P;
    JAMA Psychiatry; 2015 Mar; 72(3):284-91. PubMed ID: 25629787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials.
    Grundman M; Petersen RC; Ferris SH; Thomas RG; Aisen PS; Bennett DA; Foster NL; Jack CR; Galasko DR; Doody R; Kaye J; Sano M; Mohs R; Gauthier S; Kim HT; Jin S; Schultz AN; Schafer K; Mulnard R; van Dyck CH; Mintzer J; Zamrini EY; Cahn-Weiner D; Thal LJ;
    Arch Neurol; 2004 Jan; 61(1):59-66. PubMed ID: 14732621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.